In line with this, it would appear that the development of AR small-molecule ligands with improved pharmacokinetic properties has the potential to address key gaps in IHD management, ultimately advancing the therapeutic landscape for cardiovascular diseases [146,147]. The gene discussed is AR; the disease is myocardial ischemia.